Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06366451

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

Sponsor: AstraZeneca

Conditions Head and Neck Squamous Cell Carcinoma

Interventions AZD9592 AZD9592 + Pembrolizumab AZD9592 + Rilvegostomig AZD9592 + Sabestomig AZD9592 + Volrustomig Pembrolizumab Rilvegostomig Sabestomig Volrustomig

Updated 5 times since 2024 Last updated: Jan 16, 2025 Started: May 22, 2024 Primary completion: Feb 28, 2025 Completion: Apr 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Head and Neck Squamous Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Feb 2025 — Sep 2025 [monthly]

Recruiting EARLY_PHASE1
Sep 2024 — Feb 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Presage Biosciences

Data source: Presage Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials